A Phase 3 interventional study of WS016 in Hyperkalemia, sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD.. Recruiting at 50 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Waterstone Pharmaceutical (Wuhan) Co., LTD. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Hyperkalemia with a site in China — 7 open to participants now, 8 under way, 3 of them phase 3. Hyperkalemia · China.
Among the 20 studies in Hyperkalemia with a site in China, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 3, and was the 20th registered.
133 studies on the registry are indexed under Hyperkalemia; 25 are open to participants now.
Browse Hyperkalemia studies →7 of the 20 studies in Hyperkalemia with a site in China are open now. Recruiting first, the newest first:
Xiujuan Zang · Sites in China
Ages 18+
Peking University First Hospital · Sites in China
Ages 18–99
Waterstone Pharmaceutical (Wuhan) Co., LTD. · Sites in China
Ages 18+
Waterstone Pharmaceutical (Wuhan) Co., LTD. · Sites in China
Ages 18+
Peking University First Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 15 Hyperkalemia studies recruiting now, 10 (67%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 300 is above the median of 87 across 102 interventional studies indexed under Hyperkalemia.
Median enrollment 270 across the 13 interventional studies, 887 across the 7 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 7 most frequent:
Waterstone Pharmaceutical (Wuhan) Co., LTD. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Waterstone Pharmaceutical (Wuhan) Co., LTD. has 4 studies filed under Hyperkalemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperkalemia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07251309Phase 3Waterstone Pharmaceutical (Wuhan) Co., LTD.A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Hyperkalemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is an open-label, consisting of 2 phases, corrective phase (CP) and a maintenance phase (MP). The corrective phase aims to correct hyperkalemia within 24 to 72 hours, the maintenance phase aims to maintain the serum potassium level of subjects in the normal range for 12-month extension study carried out in participants who come from the first phase and meet certain inclusion criteria.
Eligible participants with hyperkalemia will first receive oral WS016 (12g) three times daily, over 24 to 72 hours.
After the corrective treatment, participants whose serum potassium is within the normal range will be enter the open-label maintenance phase to receive WS016 for 12-month, starting at 12g once daily, with subsequent dose adjustments based on serum potassium levels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: WS016
There is no other interventions in this clinical study.
Percentage of subjects with the mean serum potassium ≤5.0 mmol/L during maintenance phase
Time frame: Maintenance phase 12-month
Adverse events, serious adverse events, treatment-related adverse events, treatment-related serious adverse events and their incidences in subjects in the corrective phase
Time frame: Through 24 to 72 hours corrective phase
Adverse events, serious adverse events, treatment-related adverse events, treatment-related serious adverse events and their incidences in subjects in the Maintenance phase
Time frame: Through 12-month Maintenance phase
Mean change from baseline in serum potassium at all time points of corrective phase
Time frame: Through 24 to 72 hours corrective phase
Exponential rate of change in serum potassium during the corrective phase
Time frame: Through 24 to 72 hours corrective phase
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Feb 2029, 28 months after the start.
Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 28 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: WS016
Waterstone Pharmaceutical (Wuhan) Co., LTD.